IL1B and non-Hodgkin lymphoma: Compared with pre-treatment, NHL patients’ subgroups serum levels post-treatment reported significant decrease in median values of IL-1β, TNF-α, MCP-1, and eotaxin (P<0.01 each) while IL-6, G-CSF, and IL-10 showed insignificant differences at CR patients.